ORecent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving treatments for melanoma.

The possibility to use targeted and immune-based drugs alone, in combination, or in sequence, able to improve responses to overcome the resistance, to potentiate the action of immune system with the new immunomodulating antibodies, and identification of biomarkers that can predict the response to a particular therapy, represent actual concepts and approaches in the clinical management of melanoma.

Melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival.

Since then, improved understanding of the tumor microenvironment and tumor immuno-evasion strategies has resulted in different approaches to target and harness the immune response.

Approval of new immune- and target-therapies have further improved outcomes for patients with advanced melanoma.

The therapies offer the opportunity for various approaches with distinct modes of action being used in combination with one another, as well as combined with other treatment modalities such as radiotherapy, electrochemotherapy and surgery.

This year latest findings in melanoma research and advances on themes of paramount importance for melanoma prevention, diagnosis and treatment, will be discussed in the session dedicated to system biology on immunotherapy, immunogenicity and gene expression profiling and focused on the progresses of melanoma research on biomarkers/precision medicine and on combination strategies.

Then, the “Great Debate” sessions, where counterpoint views from leading experts on specific and very actual controversial clinical issues will be presented and discussed from different points of view.

In order to disclose and stimulate the discussion of new approaches and strategies in the field of melanoma  and, based on the increasing success of “Melanoma Bridge” events over the years since 2011, a panel of international faculty will join the congress that will be held in Naples in December 2022.

RESPONSABILE SCIENTIFICO

Prof. PAOLO A. ASCIERTO - Direttore Dipartimento Oncologia Medica Melanoma, Immunoterapia Oncologica e Terapie Innovative, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Napoli

Questo evento sarà accreditato per le seguenti professioni:

BIOLOGO

FARMACISTA - Farmacia Ospedaliera, Farmacia Territoriale

INFERMIERE

MEDICO CHIRURGO - Allergologia e Immunologia Clinica, Anatomia Patologica, Chirurgia Generale, Chirurgia Plastica e Ricostruttiva, Cure Palliative, Dermatologia e Venereologia, Ematologia, Epidemiologia e Sanità Pubblica, Farmacologia e Tossicologia Clinica, Genetica Medica, Igiene, Laboratorio Di Genetica Medica, Medicina Generale, Medicina Interna, Medicina Nucleare, Oncologia, Patologia Clinica, Radioterapia, Radiodiagnostica

Per iscriversi si prega di contattare la Segreteria all'indirizzo rigamonti@3psolution.it

For any technical issue please contact our website Help desk service at help@3psolution.it